All news from Pulmonary Medicine

Mechanism Used by Lung Cancer Cells to Obtain Glucose Identified

Scientists at the UCLA Jonsson Comprehensive Cancer Center have identified sodium glucose transporter 2, or SGLT2, as a mechanism that lung cancer cells use to obtain glucose, which is key to their survival and promotes tumor growth. The finding provides evidence that SGLT2 may be a novel biomarker that scientists can use to help diagnose precancerous lung lesions and early-stage lung cancers.

Tarloxotinib Against HER2 Barrier in Lung Cancer, Study

The HER2 gene is a well-known driver of breast cancer, where changes in this gene are found in about 1-in-5 cases of the disease. HER2 also contributes to about 3 percent of lung cancers, representing about 6,500 patients per year. But while drugs like trastuzumab and lapatinib have proven effective in silencing the action of HER2 in breast cancer, there are currently no approved HER2-targeted therapies for the treatment of lung cancer.

COPD: For Treatment, Tailored Approaches for Deadly Lung Disease are Considered

Valerie Chang kept waking up breathless in the middle of the night. As a regular swimmer and non-smoker, she figured it was a fluke, a remnant of her childhood asthma, perhaps. But after a lung test, doctors told her that she had the chronic obstructive pulmonary disease (COPD); her lung function was only 30% and she had done irreversible damage to her lungs. Unfortunately, they said, there was nothing they could do to improve her lung function, and she would likely need a transplant in a year.

Lorbrena Approved for ALK-positive Metastatic NSCLC

Pfizer Inc. announced that the US Food and Drug Administration (FDA) has approved LORBRENA [lor-BREN-ah] (lorlatinib), a third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease; or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

Shorter Therapy for Pulmonary Tuberculosis, Study Findings

Almost half of the nearly 10 million patients with active tuberculosis each year could have been cured with lesser treatments than current guidelines, UC San Francisco has found. The results suggest targeted therapies could be more effective in treating TB, which killed an estimated 1.3 million people around the world last year.

Benefits of Using Triple Dual Therapies in Patients with COPD Demonstrated

The InforMing the PAthway of COPD Treatment (IMPACT) study was conducted to assess the benefits of triple versus dual therapy in patients with COPD. In a study at CHEST, researchers found that regardless of baseline reversibility, the usage of triple dual therapies significantly reduced the annual rate and moderate-to-severe and severe exacerbations, improved lung function and overall quality of life in patients.